Skip to content

Released Nov 5, 2025, after the close

10-Q filed Nov 5, 2025, 36 days after period end · 0001628280-25-049697

Q3 2025 · 10-Q
Revenue$52.29M+1.5% vs Q3 2024+14.7% vs Q2 2025
Net Income-$5.48MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.04N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$27,551,000−5.0%
Operating Income-$9,192,000N/M
Operating Cash Flowderived-$3,898,000N/M
Free Cash Flowderived-$4,555,000N/M
Margins · derived
Gross margin52.7%−3.6 pt vs Q3 2024
Operating margin-17.6%−9.3 pt vs Q3 2024
Net margin-10.5%−12.3 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$52.29M$51.50M$48.00M$40.48M
Net Income-$5.48M$941.00K-$6.46M$1.63M
EPS Diluted-$0.04$0.01-$0.05-$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR